SNX-111 neuron-specific calcium channel blocker: FDA lifted the hold placed on NXCO's Phase II trials due to recumbent hypotension that had been occurring with

By WIR Staff | May 15, 1995 | 7:00 AM GMT

Neurex Corp. (NXCO), Menlo Park, Calif.
Product:

Read the full 73 word article

How to gain access

Continue reading with a
two-week free trial.